Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 4 Progression-free survival, according to treatment group

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

IDH1 mutant glioma cells are sensitive to TMZ

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Histopathology of low-grade glioma

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 2 Multiscale modelling in oncology

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Molecular subgroups of glioblastoma,

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 3 Intracranial targeting of high-grade gliomas

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Focus on central nervous system neoplasia

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Haematoxylin and eosin staining

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Gliomas—genetic landscape and biomarkers

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

chemotherapy for patients with MC versus those with AC

Figure 4 Tracheal endoscopy in two patients

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Frequency and overlap of alterations

Figure 3 Overall survival, according to treatment group

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.204 Figure 4 Current post-surgery treatment strategies for major glioma entities classified according to the 2016 WHO Classification of Tumours of the Central Nervous System Figure 4 | Current post-surgery treatment strategies for major glioma entities classified according to the 2016 WHO Classification of Tumours of the Central Nervous System22. a | Standard post-surgery treatments of IDH-mutant adult gliomas. b | Standard post-surgery treatments of IDH-wild-type adult gliomas. c | Standard post-surgery treatments of common paediatric glioma entities. Dashed arrows indicate different treatment options depending on clinical risk factors in patients with WHO grade II gliomas. PCV, procarbazine, CCNU (lomustine), and vincristine; RT, radiotherapy; SEGA, subependymal giant-cell astrocytoma; TMZ, temozolomide; TMZ/RT→TMZ, radiotherapy with concomitant and maintainance temozolomide. *Diffuse astrocytoma, IDH-wild-type (WHO grade II) and anaplastic astrocytoma, IDH-wild-type (WHO grade III) are provisional entities according to the 2016 WHO classification. Reifenberger, G. et al. (2016) Advances in the molecular genetics of gliomas — implications for classification and therapy Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.204